----item----
version: 1
id: {AEA09C7D-E633-4370-B28A-629238997795}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/23/Clovis NSCLC Drug Rociletinib Wins FDA Priority Review
parent: {E8CB3B12-58E6-4D8C-926D-C49922785188}
name: Clovis NSCLC Drug Rociletinib Wins FDA Priority Review
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 364c6f1a-7698-49dc-ae81-befab6cf5c58

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 116

{1D288E18-BAFF-4498-B284-EF9BC8D32E30}|{3B33748A-17E9-4241-8447-989BB3484DFB}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 54

Clovis NSCLC Drug Rociletinib Wins FDA Priority Review
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 54

Clovis NSCLC Drug Rociletinib Wins FDA Priority Review
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1560

<p>After the U.S. markets closed on Sept. 29, Clovis Oncology, Inc. said the FDA had granted a priority review to the firm's new drug application (NDA) for rociletinib as a treatment for patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation. </p><p>The FDA, which designated rociletinib as a breakthrough therapy last year, set March 30, 2016 as the <i>Prescription Drug User Fee Act</i> action date for rociletinib, an oral, targeted covalent mutant-selective inhibitor of EGFR.</p><p>The company also disclosed a second piece of good news to its investors &ndash; revealing the European Medicines Agency also had accepted the marketing authorization application for rociletinib, and the its Committee for Medicinal Products for Human Use (CHMP) granted an accelerated assessment for the drug, which means the time limit will be reduced from 210 days to 150 for the CHMP to reach an opinion. </p><p>An accelerated assessment is granted in recognition of the likelihood that a therapeutic will be of major public health interest in the EU, given the importance of therapeutic innovation in a patient population that exhibits a high unmet need.</p><p>Shares of Clovis got a nearly 3% boost in after-hours trading on the news of the U.S. and European regulatory actions.</p><p>The U.S. and EU submissions were based on data from Clovis' pivotal single-arm TIGER-X and TIGER-2 trials, the company said.</p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 376

<p>After the U.S. markets closed on Sept. 29, Clovis Oncology, Inc. said the FDA had granted a priority review to the firm's new drug application (NDA) for rociletinib as a treatment for patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 54

Clovis NSCLC Drug Rociletinib Wins FDA Priority Review
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150923T235945
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150923T235945
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150923T235945
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029912
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 54

Clovis NSCLC Drug Rociletinib Wins FDA Priority Review
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

199200264
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360647
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042457Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

364c6f1a-7698-49dc-ae81-befab6cf5c58
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042457Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
